Semi-Annual Balance Sheet

DAIKEN MEDICAL CO.,LTD - Filing #7541406

Concept As at
2023-09-30
As at
2023-03-31
Semi-annual balance sheet
Balance sheet
Assets
Current assets
Cash and deposits
2,657,507,000 JPY
2,516,212,000 JPY
Other
83,750,000 JPY
77,217,000 JPY
Allowance for doubtful accounts
-94,000 JPY
-94,000 JPY
Current assets
6,903,097,000 JPY
6,638,560,000 JPY
Non-current assets
Property, plant and equipment
4,036,247,000 JPY
4,070,238,000 JPY
Property, plant and equipment
Buildings
Buildings, net
1,818,757,000 JPY
1,861,600,000 JPY
Land
1,703,670,000 JPY
1,703,670,000 JPY
Other
Other, net
513,818,000 JPY
504,967,000 JPY
Intangible assets
Intangible assets
8,187,000 JPY
9,406,000 JPY
Investments and other assets
Investments and other assets
301,161,000 JPY
295,198,000 JPY
Deferred tax assets
230,596,000 JPY
230,596,000 JPY
Other
95,216,000 JPY
89,253,000 JPY
Allowance for doubtful accounts
-24,650,000 JPY
-24,650,000 JPY
Non-current assets
4,345,596,000 JPY
4,374,843,000 JPY
Assets
11,248,693,000 JPY
11,013,404,000 JPY
Liabilities
Current liabilities
Short-term borrowings
1,200,000,000 JPY
1,000,000,000 JPY
Income taxes payable
234,940,000 JPY
242,047,000 JPY
Other
284,283,000 JPY
221,329,000 JPY
Current liabilities
3,607,181,000 JPY
3,369,464,000 JPY
Non-current liabilities
Non-current liabilities
817,195,000 JPY
1,046,792,000 JPY
Long-term borrowings
793,409,000 JPY
1,013,395,000 JPY
Other
23,786,000 JPY
33,397,000 JPY
Liabilities
4,424,377,000 JPY
4,416,257,000 JPY
Other liabilities
Other liabilities
Net assets
Share capital
495,875,000 JPY
495,875,000 JPY
Shareholders' equity
Capital surplus
Capital surplus
400,875,000 JPY
400,875,000 JPY
Retained earnings
Retained earnings
7,727,753,000 JPY
7,506,089,000 JPY
Treasury shares
-1,826,583,000 JPY
-1,826,583,000 JPY
Shareholders' equity
6,797,920,000 JPY
6,576,256,000 JPY
Net assets
6,824,316,000 JPY
6,597,146,000 JPY
Share acquisition rights
26,396,000 JPY
20,890,000 JPY
Liabilities and net assets
11,248,693,000 JPY
11,013,404,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.